Navigation Links
FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman
Date:4/17/2013

ANN ARBOR, Mich. For nearly two years, University of Michigan neurologist Eva Feldman, M.D., Ph.D. has led the nation's first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig's disease.

Now, a new approval from the U.S. Food and Drug Administration paves the way for U-M to become the second site in the trial, pending approval of the U-M Institutional Review Board. To date, the first phase of the trial has taken place at Emory University, with Feldman serving as principal investigator.

The FDA approval of a Phase II trial was announced today by Neuralstem, the company whose product the trial is testing. The Phase II trial will continue to evaluate the safety of the stem cell injections, delivered directly into patients' spinal cords in escalating doses of up to 400,000 cells per injection, with a maximum of 40 injections. It will also assess any signs that the injections might be impacting patients' ALS symptoms or progression.

Feldman serves as an unpaid consultant to the company, and has led the analysis of results from the Phase I trial. In data presented last year, spinal cord injections of up to 100,000 cells were delivered safely and tolerated well -- with possible signs that in one subgroup of participants, ALS progression may have been interrupted.

"In Phase II, we'll be injecting stem cells into the upper part of the spinal cord, and our goal is to continue to assess whether this approach is safe, and to look at whether this approach offers some benefit to our patients. We are very pleased at the potential to bring this trial to the University of Michigan, where the initial research behind this technology was done -- as well as having it continue at Emory," says Feldman, the Russell N. DeJong Professor of Neurology at the U-M Medical School, research director of U-M's ALS Clinic, and director of U-M's A. Al
'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related biology news :

1. King Richard III search in new phase after discovery has potential to rewrite history
2. National Geographic unveils new phase of genographic project
3. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
4. In beef production, cow-calf phase contributes most greenhouse gases
5. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
6. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
7. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
8. New clinical trial explores novel noninvasive colon cancer screening test
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
11. Trial launched into curry chemicals cancer-fighting properties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... have marine biologists come to learn about the eye-opening characteristics ... bones of whale carcasses. With each new study, scientists ... Osedax , a genus of mouthless and gutless "bone worms" ... In the latest finding, scientists at Scripps Institution of Oceanography ...
... pilot study suggest that a virtual patient advocate (VPA) ... healthier pregnancies. Developed at Boston University School of Medicine ... is an innovative tool developed to deliver preconception care ... The study results, which are published online ...
... University professorsDavid Heeger, Joseph LeDoux, and Ruth Nussenzweighave been ... D.C.-based organization announced today. Heeger and LeDoux, ... and Department of Psychology, and Nussenzweig, a professor in ... were among the 84 new members and 21 foreign ...
Cached Biology News:Bizarre bone worms emit acid to feast on whale skeletons 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 33 NYU faculty elected to National Academy of Sciences 2
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... solopack Gold cells reduce the time and effort needed ... Amy Duncan Bruce,Jerpseth Alan Greener ,Stratagene ... , strain* in an easy-to-use, single-reaction format ... 9 transformants/g of,supercoiled DNA or the competent efficiency ...
... purification from a more versatile vector , ... ,Epitope Tagging in E. coli , Katherine Felts ... ,Stratagene , Stratagene has improved the Affinity ... vector. This new E. coli cloning and expression,vector ...
... data with the MutaTrak electronic notebook , G. ... Hamovitch Doug Schroeder ,Solana Consulting Group, Solana Beach, ... record Big,Blue transgenic rodent ... entered in a logical order and updated easily,as an ...
Cached Biology Technology:XL10-Gold Cells Supplied in New Single-Reaction Format 2XL10-Gold Cells Supplied in New Single-Reaction Format 3XL10-Gold Cells Supplied in New Single-Reaction Format 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 2High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 3High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 5High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 6High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 7High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 8Organize Your Data from the Big Blue Mutation Assay 2Organize Your Data from the Big Blue Mutation Assay 3
Lipid Phosphate Phosphohydrolase 2...
Request Info...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Biology Products: